Influence of CYP3A activity on the efficacy and safety of fluvoxamine in patients depressive disorders and comorbid alcohol use disorder [Влияние...
Застрожин М. С., Смирнов В. В., Сорокин А. С., Grishina E. A., Ryzhikova K. A., Бедина И. А., Шипицyн В. В., Савченко Л. М., Бузик О. З. Х., Копоров С. Г., Bryun E. A., Sy'chev D. A.
Вестник Российской академии медицинских наук
Т. 73, Вып. 6, С. 411-419
Опубликовано: 2018
Тип ресурса: Статья
Аннотация:
BACKGROUND: Alcohol dependence is often combined with affective disorders, in particular, depressive disorder (DD), which worsens adversely affects the prognosis of the course of both diseases and their outcomes. For the treatment of DD, drugs from the group of selective serotonin reuptake inhibitors, whose representative is fluvoxamine, are used. Fluvoxamine therapy is often associated with a risk of development is shown to be ineffective, and a part of patients develop dose-dependent adverse drug reactions (ADR) and pharmacoresistance. OBJECTIVE: To study the effects of CYPD6 isoenzyme activity on the efficacy and safety of fluvoxamine therapy in patients with depressive disorders, comorbid with alcoholism. METHODS: The study was conducted on 117 Russian patients with DD, alcohol-dependent comorbid. For the purpose of correction of depressive disorders within the framework of cyclothymia, fluvoxamine (Fevarin) was administered to patients at a dosage of 50−150 mg/day. Genotyping was
Ключевые слова:
CYP2D6; Fluvoxamine; Personalized medicine; Pharmacogenetics; Pinoline
Язык текста: Русский
ISSN: 0869-6047
Застрожин М. С.
Смирнов В. В. Валерий Валерьевич 1985-
Сорокин А. С.
Grishina E. A.
Ryzhikova K. A.
Бедина И. А.
Шипицyн В. В.
Савченко Л. М.
Бузик О. З. Х.
Копоров С. Г.
Bryun E. A.
Sy'chev D. A. Dmitrij Alekseevich 1975-
Zastrozhin M. S.
Smirnov V. V. Valerij Valeryevich 1985-
Sorokin A. S.
Гришина Е. А.
Рyжикова К. А.
Bedina I. A.
Shipitsyn V. V.
Savchenko L. M.
Buzik O. Z. H.
Koporov S. G.
Брюн Е. А.
Сычев Д. А. Дмитрий Алексеевич 1975-
Influence of CYP3A activity on the efficacy and safety of fluvoxamine in patients depressive disorders and comorbid alcohol use disorder [Влияние активности CYP2D6 на эффективность и безопасность флувоксамина у пациентов с депрессивными расстройствами, коморбидными с алкогольной зависимостью]
Influence of CYP3A activity on the efficacy and safety of fluvoxamine in patients depressive disorders and comorbid alcohol use disorder [Влияние...
Текст визуальный непосредственный
Вестник Российской академии медицинских наук
Издательство "Педиатръ"
Т. 73, Вып. 6 С. 411-419
2018
Статья
CYP2D6 Fluvoxamine Personalized medicine Pharmacogenetics Pinoline
BACKGROUND: Alcohol dependence is often combined with affective disorders, in particular, depressive disorder (DD), which worsens adversely affects the prognosis of the course of both diseases and their outcomes. For the treatment of DD, drugs from the group of selective serotonin reuptake inhibitors, whose representative is fluvoxamine, are used. Fluvoxamine therapy is often associated with a risk of development is shown to be ineffective, and a part of patients develop dose-dependent adverse drug reactions (ADR) and pharmacoresistance. OBJECTIVE: To study the effects of CYPD6 isoenzyme activity on the efficacy and safety of fluvoxamine therapy in patients with depressive disorders, comorbid with alcoholism. METHODS: The study was conducted on 117 Russian patients with DD, alcohol-dependent comorbid. For the purpose of correction of depressive disorders within the framework of cyclothymia, fluvoxamine (Fevarin) was administered to patients at a dosage of 50−150 mg/day. Genotyping was